Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.91, $0.20 better than the analyst estimate of $0.71. Revenue for the quarter came in at $207.6 million versus the consensus estimate of $189.6 million.

GUIDANCE:

Repligen sees FY2022 EPS of $3.13-$3.20, versus the consensus of $3.09. Repligen sees FY2022 revenue of $790-810 million, versus the consensus of $789 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.